3 results
To measure APC resistance and SHBG levels as indicators of the risk of venous thrombosis during use of the new developed combined oral contraceptive containing dienogest/estradiolvalerate (Qlaira®) compared with a combined oral contraceptive…
Primary Objective:1. To evaluate the efficacy of sonelokimab at 2 different dose levels (120 mg, 240 mg) compared with placebo in the treatment of participants withactive moderate to severe hidradenitis suppurativa.Secondary Objectives:1. To…
The primary objective of the VertiGO! trial is to assess the feasibility of restoring vestibular function by making use of prolonged VI stimulation. This will be done using a combined VI and CI device: The CVI. To achieve this objective, patients…